SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin
Status:
Completed
Trial end date:
2022-05-24
Target enrollment:
Participant gender:
Summary
This is the phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate
the efficacy and long-term safety of SAL067 in T2DM patients uncontrolled by metformin,
comprising 24 weeks of double-blind treatment period followed by an open-label treatment
period, making up a total of 52 weeks.